Azenta (AZTA)
(Delayed Data from NSDQ)
$43.98 USD
-1.02 (-2.27%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $43.99 +0.01 (0.02%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.98 USD
-1.02 (-2.27%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $43.99 +0.01 (0.02%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth B Momentum B VGM
Zacks News
Azenta (AZTA) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Brooks (AZTA) delivered earnings and revenue surprises of 128.57% and 4.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Enovis (ENOV) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Enovis (ENOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Azenta (AZTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Brooks (AZTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Azenta (AZTA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Azenta (AZTA) stock based on the movements in the options market lately.
Hyperfine (HYPR) to Release ACTION PMR Study Data for Swoop
by Zacks Equity Research
Hyperfine (HYPR) is set to release study data in August 2024, showing the value of the Swoop system in enabling critical stroke treatment choices in urgent care settings.
New Strong Buy Stocks for July 16th
by Zacks Equity Research
BTG, APOG, AZTA, AFYA and KGC have been added to the Zacks Rank #1 (Strong Buy) List on July 16, 2024.
10x Genomics (TXG) Surges 8.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
10x Genomics (TXG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 96.97% and 1.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Inspire Medical Systems (INSP) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 1,325% and 0.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Outset Medical, Inc. (OM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hims & Hers Health, Inc. (HIMS) Moves 8.3% Higher: Will This Strength Last?
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
3 Stocks to Watch After Impressive Earnings Beats
by Shaun Pruitt
In a somewhat quiet earnings lineup this week, several stocks stand out after posting strong quarterly results on Monday.
Azenta (AZTA) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Brooks (AZTA) delivered earnings and revenue surprises of 533.33% and 8.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
American Well Corporation (AMWL) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
American Well Corporation (AMWL) delivered earnings and revenue surprises of -9.52% and 4.59%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 103.57% and 4.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Azenta (AZTA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Brooks (AZTA) delivered earnings and revenue surprises of -20% and 8.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health, Inc. (HIMS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 16.67% and 6.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 23% and 7.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Down -23.84% in 4 Weeks, Here's Why You Should You Buy the Dip in Brooks (AZTA)
by Zacks Equity Research
Brooks (AZTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Azenta (AZTA) Beats Q1 Earnings Estimates
by Zacks Equity Research
Brooks (AZTA) delivered earnings and revenue surprises of 100% and 1.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Azenta (AZTA) Q3 Earnings Beat Estimates
by Zacks Equity Research
Brooks (AZTA) delivered earnings and revenue surprises of 50% and 0.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics, Inc. (FLGT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 6.85% and 2.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Azenta (AZTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Brooks (AZTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Azenta (AZTA) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Brooks (AZTA) delivered earnings and revenue surprises of 9.09% and 2.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
1Life Healthcare, Inc. (ONEM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
1Life Healthcare, Inc. (ONEM) delivered earnings and revenue surprises of 4.08% and 2.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?